P

Pharmimpulse

BE0634.979.024

About Pharmimpulse

Pharmimpulse is a general partnership (VOF/SNC) based in Lasne, founded in 2015. Its main activity is classified as "Activiteiten van uitzendbureaus en andere diensten in verband met personeelsvoorziening". For the 2025 financial year, Pharmimpulse reported a loss of €81,057. A year earlier, in 2024, it still made a profit of €3,416. Revenue was not published, which is common for abbreviated accounts. The gross margin came to €171,172, down 80% on 2024. It employed an average of 5.7 full-time equivalents. Equity is negative (-€77,307): liabilities exceed assets. In 2016 it was €3,750. 9 annual accounts are available, covering 2016 to 2025.

Juridical situation
Normal situation
Company number
0634.979.024
Founding date
Founded on 11-08-2015
EUID number
BEKBOBCE.0634.979.024
Type of enterprise
Rechtspersoon
Location
Rue De La Bachée 86 Lasne 1380
Juridical form
VOF — General partnership (VOF/SNC)

Publications 2

All publications

Frequently asked questions

Answers to the most common questions about Pharmimpulse, based on official government data and the filed annual accounts.

What is the VAT number of Pharmimpulse?

The VAT number of Pharmimpulse is BE0634.979.024.

When was Pharmimpulse established?

Pharmimpulse was founded in 11-08-2015.

What is the official address of Pharmimpulse?

The official address of Pharmimpulse is Rue De La Bachée 86 Lasne 1380.

What is the legal form of Pharmimpulse?

The juridical form of Pharmimpulse is General partnership (VOF/SNC).

What is the annual revenue of Pharmimpulse?

Pharmimpulse has not (yet) filed an annual report, so there are no revenue figures available.

Is Pharmimpulse a reliable company?

Pharmimpulse is a registered Rechtspersoon with company number 0634.979.024 and can be verified through the official CBE database.

What is the credit limit of Pharmimpulse?

The estimated credit limit of Pharmimpulse is €0.

Is Pharmimpulse still active?

Pharmimpulse currently has the status "Normal situation" and is active.

Further reading

View all insights

Sources